Ribonova Inc

RiboNova Inc is a biopharmaceutical company based in Bryn Mawr, PA, dedicated to discovering and developing innovative medicines for patients suffering from serious rare diseases, with a particular focus on mitochondrial disease. With a lead product candidate, R007, a Phase-2 ready small molecule, RiboNova aims to provide effective treatment options for individuals affected by inherited mitochondrial disease.

With an estimated 75,000 people in the United States affected by mitochondrial disease, RiboNova's mission is to address the significant burden of this devastating rare disease by leveraging their expertise in tRNA drug discovery and mitochondrial research. Through their commitment to research and development, RiboNova strives to make a meaningful impact on the lives of patients and their families who are affected by mitochondrial disease.

Generated from the website